September 21, 2020 — The FNIH Biomarkers ConsortiumSarcopenia 2 project, Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability, recently achieved the key milestone of publishing seven articles in The Journal of the American Geriatrics Society and The Journals of Gerontology.
June 8, 2020 — For the sixth year in a row, the Foundation for the National Institutes of Health (FNIH) has earned the top designation of four-star honors from the nation’s largest independent charity evaluator, Charity Navigator. Only 9 percent of charities evaluated by the group have received this highest rating for at least six consecutive years, indicating that the FNIH “outperforms most charities in America.”
June 3, 2020 – The Foundation for the National Institutes of Health (FNIH) has announced a new project that will test whether an antibiotic taken during labor can prevent infections in mothers and newborns in seven low- and middle-income countries. This study will be conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) through their Global Network for Women’s and Children’s Health Research (Global Network) with funding from the Bill & Melinda Gates Foundation.
May 15, 2020 — The FNIH Biomarkers Consortium program Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) has received acceptance from the U.S. Food and Drug Administration (FDA) for its Letter of Intent (LOI). NIMBLE seeks to qualify biomarkers to easily diagnose clinically significant non-alcoholic steatohepatitis, or NASH.
March 12, 2020 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project under its Neuroscience Steering Committee that will identify the best blood tests to aid in the early detection of Alzheimer’s disease.
October 21, 2019 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project under its Cancer Steering Committee that will identify biological markers (biomarkers) that predict personalized response to immunotherapy after a patient receives chemotherapy. The “Chemotherapeutic Impact on the Immune MicroEnvironment (ChIIME)” project will use a cutting-edge technology called single nucleus RNA sequencing to analyze metastatic breast cancer samples.
September 24, 2019 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project under its Cancer Steering Committee that will standardize the assessment of genetic tests that use blood samples to track cancer in hospitals and laboratories across the United States. In particular, the project will develop tools to enable clinicians to measure and confidently compare circulating tumor DNA (ctDNA) test results across different laboratories.
BETHESDA, MD, June 13, 2019 — The Foundation for the National Institutes of Health (FNIH) is proud to announce that President and Executive Director Maria C. Freire, Ph.D., has been named “Executive of the Year” by NonProfit PRO.
June 11, 2019 – The FNIH Biomarkers Consortium has launched a new project under its Metabolic Disorders Steering Committee that will standardize biological markers (biomarkers) that help diagnose Non-Alcoholic SteatoHepatitis (NASH) – a type of liver disease. The “Non-Invasive Biomarkers of Metabolic Liver DiseasE (NIMBLE)” project will directly compare imaging and blood-based biomarkers to biopsy results to define the best tools for diagnosing NASH.
April 23, 2019 - The Foundation for the National Institutes of Health (FNIH) has received top honors again this year from Charity Navigator by earning it’s coveted 4-star rating. Charity Navigator, the nation’s largest independent charity evaluator, has recognized the FNIH with its highest rating for demonstrating strong financial health and commitment to accountability and transparency.
